Investors care about many things, but when they say scale, they mean revenue. Two times, five times, ten times… whatever the directive, it’s centered on revenue growth. For leadership teams, the focus on revenue milestones is more nuanced. Each one matters to investors, yes. But each also marks a strategic shift. The decisions, disciplines, and … Read more
The loss of lean muscle mass has long been a concern for patients using GLP-1 therapies. New results from the Regeneron Phase 2 COURAGE trial, led by Julio Rosenstock, MD, at Velocity’s site in Dallas, TX, point to a potential solution. The study indicates that combining semaglutide with trevogrumab (anti-GDF8/anti-myostatin) helped prevent about half of the lean … Read more
Julio Rosenstock, MD, was the lead author of Phase 2 trial results evaluating orforglipron, an oral GLP-1 receptor agonist, published in Diabetes, Obesity and Metabolism. The study found that orforglipron doses of 12 mg and higher significantly improved β-cell function and insulin sensitivity in participants with type 2 diabetes (T2D). These results support orforglipron’s potential … Read more
It’s a cliché at this point to say AI (artificial intelligence) is the future; there are people still struggling to work their smartphones who could tell you that. AI tools are too capable, and the commercial advantage too significant, for them not to become a sizeable part of our work and personal lives. But the … Read more
Velocity Clinical Research is pleased to announce the appointment of Sarah Smiley, DO, FACP, as its new Chief Physician Officer (CPO), reinforcing the company’s commitment to clinical leadership as it continues to grow its global site network and deepen its therapeutic expertise. Dr. Smiley is a seasoned physician investigator with nearly two decades of experience … Read more
Velocity Clinical Research, the world’s leading integrated research site organization, has appointed Ines Abs as its new Country Head of Germany, reinforcing its commitment to growth in Europe at a time when other site networks are retreating from the region. Ines brings over two decades of experience in clinical research operations, having held senior leadership … Read more
Velocity Clinical Research, the leading fully integrated site organization, has announced a strategic partnership with Palantir Technologies to automate and streamline the notoriously complex payments reconciliation process in clinical trials. This collaboration marks a milestone in applying advanced artificial intelligence (AI) to one of the industry’s most persistent administrative challenges. Reconciling invoices and payments in … Read more
We’re proud to share that Velocity was named a top enrolling site network for Q1 2025 by AstraZeneca, with the highest number of randomizations across their biopharma portfolio. This recognition is a testament to the dedication of our teams around the world who work every day to ensure clinical trial participants are supported, engaged, and … Read more
Velocity Principal Investigators Douglas K. Logan, MD, and David Ensz, MD, are authors of a newly published Nature Communications article, “Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.” The Phase 1/2 Moderna trial results “demonstrate the proof of concept that mRNA-1020 and mRNA-1030 elicit similar HA-specific immune responses to [hemagglutinin] HA-only … Read more
Very few physicians begin their careers with an eye on research. Moving into the role of Principal Investigator (PI) can be unexpectedly challenging, with demands that often take physicians by surprise. “Much of my experience with clinical research centered around reviewing journal articles for clinical practice,” explains Daniel Williams, DO, FAAEM, who transitioned from emergency … Read more